Intervention
entinostat
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 9 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
9 shownA Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine TherapyNCT07330544 · 2025-11-24
RECRUITINGDalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast CancerNCT07492394 · 2025-09-12
RECRUITINGEntinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailureNCT07708194 · 2025-06-23
RECRUITINGDrug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast CancerNCT02820961 · 2016-06-29
COMPLETEDPh1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)NCT02437136 · 2015-08-26
COMPLETEDStudy to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung CancerNCT01594398 · 2012-05-01
COMPLETEDEntinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by SurgeryNCT01234532 · 2010-10-01
TERMINATEDStudy to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast CancerNCT00676663 · 2008-06-13
COMPLETEDMS-275 in Treating Patients With Advanced Solid Tumors or LymphomaNCT00020579 · 2001-03-01
COMPLETEDCommon conditions
Breast Cancer6Breast Cancer, Estrogen Receptor-Positive1Cancer1ER+ Breast Cancer1Estrogen Receptor Breast Cancer1Estrogen Receptor Positive Breast Cancer1Estrogen Receptor-negative Breast Cancer1Estrogen Receptor-Positive Breast Cancer1HER2-negative Breast Cancer1HER2-positive Breast Cancer1Hormone Receptor-Positive Breast Cancer1Lung Cancer1Melanoma1Metastatic Breast Cancer1Mismatch Repair-Proficient Colorectal Cancer1Non Small Cell Lung Cancer (NSCLC)1Non-Small Cell Lung Cancer1Progesterone Receptor-negative Breast Cancer1Stage I Breast Cancer1Stage II Breast Cancer1Stage IIIA Breast Cancer1Triple-negative Breast Cancer1
Leading sponsors
Trial status mix
COMPLETED5
RECRUITING3
TERMINATED1
Phase mix
PHASE26
PHASE15
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.